Celcuity plunges after experimental breast cancer treatment data disappoints

Celcuity shares slumped 25% , set for their biggest one-day decline, on Tuesday after its experimental breast cancer treatment extended ​the period of time a patient lives without the disease ‌worsening but underperformed a previous trial.